

APPLICATION NO. 10/617,208

23379

United States Patent and Trademark Office

FILING DATE

07/10/2003

7590

03/08/2006

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONE FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

www.uspto.gov	
ATTORNEY DOCKET NO.	CONFIRMATION NO
B00-016-2	3116
EXAM	INER
KAM, CI	IIH MIN

PAPER NUMBER

RICHARD ARON OSMAN SCIENCE AND TECHNOLOGY LAW GROUP ART UNIT 242 AVE VISTA DEL OCEANO SAN CLEMEMTE, CA 92672

1656

DATE MAILED: 03/08/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

FIRST NAMED INVENTOR

Alexander N. Glazer

·	T A	T 4	
	Application No.	Applicant(s)	
	10/617,208	GLAZER ET AL.	
Office Action Summary	Examiner	Art Unit	
	Chih-Min Kam	1656	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).			
Status	,		
1) Responsive to communication(s) filed on 2a) This action is FINAL. 2b) This 3) Since this application is in condition for alloware closed in accordance with the practice under the practice.			
Disposition of Claims			
4) ☐ Claim(s) 1-22 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-22 are subject to restriction and/or Application Papers	wn from consideration.		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposite and accomposite and any objection to the Replacement drawing sheet(s) including the correct and the option of the opti	cepted or b) objected to by the drawing(s) be held in abeyance. Set tion is required if the drawing(s) is objected.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 			
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:		

Application/Control Number: 10/617,208 Page 2

Art Unit: 1656

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U. S. C. 121:

- I. Claims 1-20, drawn to a cell comprising a functional oligomeric phycobiliprotein comprising a fusion protein comprising a functional displayed domain and a functional phycobiliprotein domain; and a method of making an oligomeric phycobiliprotein by expressing fusion protein in the cell, classified in class 435, subclass 69.7, and class 435, subclass 325.
- II. Claims 21-22, drawn to a method for making a functional display domain by expressing the fusion protein comprising a functional displayed domain and a functional phycobiliprotein domain in a cell, cleaving a peptide bond between the functional displayed domain and the functional phycobiliprotein domain, and separating the functional displayed domain from the functional phycobiliprotein domain, classified in class 435, subclasses 325 and 69.1.
- 2. The inventions are distinct, each from the other because of the following reasons:

The product of Invention I and the method of Invention II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product of Invention I can be used to produce the fusion protein of a functional displayed domain and a functional phycobiliprotein domain.

Application/Control Number: 10/617,208

Art Unit: 1656

The methods of Inventions I and II are distinct from each other because the two groups contain different method steps and produce different product, e.g., Invention I produces a fusion protein of a functional displayed domain and a functional phycobiliprotein domain, while Invention II produces a functional displayed domain.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by recognized divergent subject matter, and because inventions I-II require different searches but are not co-extensive, examination of these distinct inventions would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102,

Application/Control Number: 10/617,208

Page 4

Art Unit: 1656

103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Art Unit: 1656

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr can be reached at 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Christian .

Chih-Min Kam, Ph. D.

Patent Examiner

CHIH-MIN KAM
PATENT EXAMINES

CMK

March 4, 2006